Tissue plasminogen activator: why the backlash?
- 30 June 1989
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 13 (7) , 1477-1480
- https://doi.org/10.1016/0735-1097(89)90335-5
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Thrombolytic Therapy: Current StatusNew England Journal of Medicine, 1988
- Thrombolytic Therapy: Current StatusNew England Journal of Medicine, 1988
- THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTYThe Lancet, 1988
- TPA: Is it worth the price?American Heart Journal, 1987
- A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: Initial patency and influence of maintained infusion on reocclusion rateThe American Journal of Cardiology, 1987
- A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarctionJournal of the American College of Cardiology, 1987
- Recombinant tissue plasminogen activator (rt-PA): Is it the thrombolytic agent of choice for an evolving acute myocardial infarction?The American Journal of Cardiology, 1987
- DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985